BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Pharm Country

  NurOwn: A Study in the Complexity of ALS Trials

  There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve.

  May 4, 2021

   · 

  6 min read

   · 

  Heather McKenzie
• 

  BioMidwest

  AbCellera-Eli Lilly Antibody Shows Potency Against All Current COVID-19 Variants

  Should this antibody continue to prove to be safe and effective in clinical studies, it will replace the previously authorized bamlanivimab, which has since been sidelined due to the rise of viral variants that diminished its effectiveness.

  May 4, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Neuroelectrics Bags $17.5 Million for At-Home, Personalized Brain Stimulation Platform

  Neuroelectrics, based in Barcelona, Spain with offices in Cambridge, Massachusetts, announced it had raised $17.5 million in a Series A financing round. It was led by Morningside Ventures.

  May 4, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Bio NC

  2021 COVID-19 News: Pfizer to File for Full Approval of Its Vaccine and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.

  May 4, 2021

   · 

  3 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Sarepta’s Second Muscular Dystrophy Drug Shows Greater Promise in Phase II

  Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.

  May 4, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Business

  Changing of the Guard: Four Biopharma Companies Appoint New CEOs

  Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.

  May 4, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Drug Development

  Pfizer Owes Massive $14.6 Billion Q1 Revenues to Vaccine Rollout

  Pfizer reported its first-quarter 2021 revenues of $14.6 billion, an impressive 42% operational growth.

  May 4, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Is the Dream of COVID-19 “Herd Immunity” Dead?

  In 2020, “herd immunity” was the mythical goal set forth in the hearts and minds of a struggling population, waiting on a vaccine to return us to normal. Now experts are saying herd immunity with COVID-19 may well be impossible.

  May 4, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Job Trends

  Expansions and Hirings Spark Surge of Growth in BioCapital Region

  Fueled by billions of dollars invested by the federal government to battle the ongoing COVID-19 pandemic, companies across the BioCapital region have expanded their footprint and number of employees.

  May 4, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Touting 100% Efficacy, Pfizer Vaccine Expects Approval This Week for Younger Teens

  The U.S. FDA is expected to give the go-ahead for Pfizer and BioNTech’s COVID-19 vaccine for adolescents ages 12 and older within the week.

  May 4, 2021

   · 

  2 min read

   · 

  Mark Terry